Iron
Methodology & AI Transparency ⓘ
Iron Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is iron? Iron is a mineral that our bodies need for growth and development.
- 2 Real-world patient consensus: Clinical coding for Iron uses ICD-10 K50.9 across IBS, IBD & Colon specialty care.
- 3 Typical cash cost range: Clinicians assessing Iron focus on mucosal tight-junction permeability in Iron (K50.9: shifts or immune-mediated) and targeted history.
- 4 Top reported side effects / signs: Follow-up benchmark in Iron: maintaining hs-CRP, CBC & in Iron (K50.9: Ferritin) within Normal hemoglobin; hs-CRP < 1.0 mg/L (K50.9).
Ask our AI Specialists anything about Iron
What Is Iron?
What is iron? Iron is a mineral that our bodies need for growth and development. Your body uses iron to make hemoglobin, a protein in red blood cells. Hemoglobin carries oxygen from the lungs to all parts of the body. Iron is also important for healthy muscles, bone marrow, and organ function. Your body also needs iron to make some hormones . How do you get iron? Iron is found naturally in many foods and is added to some fortified food products.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Iron (K50.9) features mucosal tight-junction permeability in Iron (K50.9: shifts or immune-mediated). Cross-referenced with NIH MeSH (Iron), therapeutic stabilization in ibs, ibd & colon is verified against Fecal Calprotectin [Iron K50.9].
Common Symptoms & Clinical Signs
- • Lean meat, seafood, and poultry
- • Iron-fortified breakfast cereals and breads
- • Presentation of Iron (K50.9): rectal bleeding, nocturnal in Iron (K50.9: bowel movements, or)
- • Secondary Iron clinical sign: recurrent lower abdominal in Iron (K50.9: cramping associated with)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Iron Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | K50.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | IBS, Crohn, Colitis & Bowel Disorders | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: hs-CRP, CBC & in Iron (K50.9: Ferritin) | Normal hemoglobin; hs-CRP < 1.0 mg/L (K50.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fecal Calprotectin [Iron K50.9] | < 50 mcg/g (K50.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Tissue Transglutaminase IgA in Iron (K50.9: (tTG-IgA)) | Negative (celiac rule-out) (K50.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Iron
Treatment selection for Iron depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Iron)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on A phase 3, multicenter, randomized, gold-standard blind, vehicle-controlled,: What a 281-Participant Study Found In the sofpironium group, common events (incidence, ≥5%) were nasopharyngitis (14.2%) and dermatitis/skin redness at the application site (8.5%/5.7%), with no serious side effects reported. The Journal of dermatology • 2021-03-15 • Phase III Randomized Trial | N = 281 | 93/100 | PMID 33410265 ↗ |
| New Insights on Benefits and safety of Subcutaneous Vedolizumab in Patients With Moderately to: What a 275-Participant Study Found Vedolizumab SC is an effective and safe maintenance therapy in patients with CD who responded to two infusions of vedolizumab intravenous induction therapy. Journal of Crohn's & colitis • 2022-01-28 • Phase III Randomized Trial | N = 275 | 93/100 | PMID 34402887 ↗ |
| New Insights on Sofpironium skin-applied gel, 12.45%, for the treatment of axillary: What a 353-Participant Study Found Sofpironium applied to the skin gel, 12.45%, applied topically once daily before bedtime is effective and well-tolerated for treatment of primary axillary hyperhidrosis in patients ≥9 years old. Journal of the American Academy of Dermatology • 2025-07-15 • Phase III Randomized Trial | N = 353 | 93/100 | PMID 40054501 ↗ |
| Can This Approach Help? Inside the Latest Research on Markers of Iron Flux during Testosterone-Mediated Erythropoiesis in Older Men Testosterone replacement of older hypogonadal men with unexplained anemia stimulates erythropoiesis associated with increased iron mobilization. The Journal of clinical endocrinology and metabolism • 2020-11-01 • Randomized Controlled Trial | N = 58 | 88/100 | PMID 32785689 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of ferric carboxymaltose infusion in reducing anemia in Common side effects in the FCM arm included neutropenia (17%), hypophosphatemia (16%), and fatigue (15%). American journal of hematology • 2021-12-01 • Phase III Randomized Trial | N = 122 | 88/100 | PMID 34653287 ↗ |
Iron Patient Community & “People Like Me” Threads
Filter Iron community threads and patient logs by age, biological sex, dosage, and treatment duration.